These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 37311413)

  • 1. Single cell clonotypic and transcriptional evolution of multiple myeloma precursor disease.
    Dang M; Wang R; Lee HC; Patel KK; Becnel MR; Han G; Thomas SK; Hao D; Chu Y; Weber DM; Lin P; Lutter-Berka Z; Berrios Nolasco DA; Huang M; Bansal H; Song X; Zhang J; Futreal A; Moreno Rueda LY; Symer DE; Green MR; Rojas Hernandez CM; Kroll M; Afshar-Khargan V; Ndacayisaba LJ; Kuhn P; Neelapu SS; Orlowski RZ; Wang L; Manasanch EE
    Cancer Cell; 2023 Jun; 41(6):1032-1047.e4. PubMed ID: 37311413
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma.
    Zavidij O; Haradhvala NJ; Mouhieddine TH; Sklavenitis-Pistofidis R; Cai S; Reidy M; Rahmat M; Flaifel A; Ferland B; Su NK; Agius MP; Park J; Manier S; Bustoros M; Huynh D; Capelletti M; Berrios B; Liu CJ; He MX; Braggio E; Fonseca R; Maruvka YE; Guerriero JL; Goldman M; Van Allen EM; McCarroll SA; Azzi J; Getz G; Ghobrial IM
    Nat Cancer; 2020 May; 1(5):493-506. PubMed ID: 33409501
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Whole-genome sequencing reveals progressive versus stable myeloma precursor conditions as two distinct entities.
    Oben B; Froyen G; Maclachlan KH; Leongamornlert D; Abascal F; Zheng-Lin B; Yellapantula V; Derkach A; Geerdens E; Diamond BT; Arijs I; Maes B; Vanhees K; Hultcrantz M; Manasanch EE; Kazandjian D; Lesokhin A; Dogan A; Zhang Y; Mikulasova A; Walker B; Morgan G; Campbell PJ; Landgren O; Rummens JL; Bolli N; Maura F
    Nat Commun; 2021 Mar; 12(1):1861. PubMed ID: 33767199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterizing the role of the immune microenvironment in multiple myeloma progression at a single-cell level.
    Schinke C; Poos AM; Bauer M; John L; Johnson S; Deshpande S; Carrillo L; Alapat D; Rasche L; Thanendrarajan S; Zangari M; Al Hadidi S; van Rhee F; Davies F; Raab MS; Morgan G; Weinhold N
    Blood Adv; 2022 Nov; 6(22):5873-5883. PubMed ID: 35977111
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The yin-yang effects of immunity: From monoclonal gammopathy of undetermined significance to multiple myeloma.
    Yi Z; Ma T; Liu J; Tie W; Li Y; Bai J; Li L; Zhang L
    Front Immunol; 2022; 13():925266. PubMed ID: 35958625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changing paradigms in diagnosis and treatment of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM).
    Ho M; Patel A; Goh CY; Moscvin M; Zhang L; Bianchi G
    Leukemia; 2020 Dec; 34(12):3111-3125. PubMed ID: 33046818
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Defining genomic events involved in the evolutionary trajectories of myeloma and its precursor conditions.
    Chojnacka M; Diamond B; Landgren O; Maura F
    Semin Oncol; 2022 Feb; 49(1):11-18. PubMed ID: 35168813
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Smoldering multiple myeloma - Past, present, and future.
    Mann H; Katiyar V; Varga C; Comenzo RL
    Blood Rev; 2022 Mar; 52():100869. PubMed ID: 34312016
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cell autonomous and microenvironmental regulation of tumor progression in precursor states of multiple myeloma.
    Manier S; Kawano Y; Bianchi G; Roccaro AM; Ghobrial IM
    Curr Opin Hematol; 2016 Jul; 23(4):426-33. PubMed ID: 27101529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Role of T Cell Immunity in Monoclonal Gammopathy and Multiple Myeloma: From Immunopathogenesis to Novel Therapeutic Approaches.
    Lagreca I; Riva G; Nasillo V; Barozzi P; Castelli I; Basso S; Bettelli F; Giusti D; Cuoghi A; Bresciani P; Messerotti A; Gilioli A; Pioli V; Colasante C; Vallerini D; Paolini A; Maccaferri M; Donatelli F; Forghieri F; Morselli M; Colaci E; Leonardi G; Marasca R; Potenza L; Manfredini R; Tagliafico E; Trenti T; Comoli P; Luppi M
    Int J Mol Sci; 2022 May; 23(9):. PubMed ID: 35563634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single-cell profiling of tumour evolution in multiple myeloma - opportunities for precision medicine.
    Dutta AK; Alberge JB; Sklavenitis-Pistofidis R; Lightbody ED; Getz G; Ghobrial IM
    Nat Rev Clin Oncol; 2022 Apr; 19(4):223-236. PubMed ID: 35017721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gene Expression Analysis of the Bone Marrow Microenvironment Reveals Distinct Immunotypes in Smoldering Multiple Myeloma Associated to Progression to Symptomatic Disease.
    Isola I; Brasó-Maristany F; Moreno DF; Mena MP; Oliver-Calders A; Paré L; Rodríguez-Lobato LG; Martin-Antonio B; Cibeira MT; Bladé J; Rosiñol L; Prat A; Lozano E; Fernández de Larrea C
    Front Immunol; 2021; 12():792609. PubMed ID: 34880879
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnosis and Management of Monoclonal Gammopathy and Smoldering Multiple Myeloma.
    Schmidt T; Callander N
    J Natl Compr Canc Netw; 2020 Dec; 18(12):1720-1729. PubMed ID: 33347744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stromal alterations in patients with monoclonal gammopathy of undetermined significance, smoldering myeloma, and multiple myeloma.
    Bogun L; Koch A; Scherer B; Fenk R; Maus U; Bormann F; Köhrer K; Petzsch P; Wachtmeister T; Zukovs R; Dietrich S; Haas R; Schroeder T; Jäger P; Geyh S
    Blood Adv; 2024 May; 8(10):2575-2588. PubMed ID: 38241490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk Stratification of Precursors to Multiple Myeloma in 2020.
    Chudasama R; Barth P
    R I Med J (2013); 2020 Apr; 103(3):46-47. PubMed ID: 32236162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progress in the Management of Smoldering Multiple Myeloma.
    Schmidt TM; Callander NS
    Curr Hematol Malig Rep; 2021 Apr; 16(2):172-182. PubMed ID: 33983517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering myeloma (SMM): a practical guide to management.
    Maciocia N; Wechalekar A; Yong K
    Hematol Oncol; 2017 Dec; 35(4):432-439. PubMed ID: 27804161
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The spectrum of somatic mutations in monoclonal gammopathy of undetermined significance indicates a less complex genomic landscape than that in multiple myeloma.
    Mikulasova A; Wardell CP; Murison A; Boyle EM; Jackson GH; Smetana J; Kufova Z; Pour L; Sandecka V; Almasi M; Vsianska P; Gregora E; Kuglik P; Hajek R; Davies FE; Morgan GJ; Walker BA
    Haematologica; 2017 Sep; 102(9):1617-1625. PubMed ID: 28550183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: a review of the current understanding of epidemiology, biology, risk stratification, and management of myeloma precursor disease.
    Agarwal A; Ghobrial IM
    Clin Cancer Res; 2013 Mar; 19(5):985-94. PubMed ID: 23224402
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In multiple myeloma, circulating hyperdiploid B cells have clonotypic immunoglobulin heavy chain rearrangements and may mediate spread of disease.
    Pilarski LM; Giannakopoulos NV; Szczepek AJ; Masellis AM; Mant MJ; Belch AR
    Clin Cancer Res; 2000 Feb; 6(2):585-96. PubMed ID: 10690543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.